newsfilter
← Latest News
GlobeNewswire·

DICE Therapeutics Reports Second Quarter 2022 Financial Results and Recent Highlights

Completed enrollment in Phase 1 clinical trial of lead oral IL-17 antagonist DC-806; topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- DI